论文部分内容阅读
应用放免及生化法对１０７例卵巢肿瘤患者及５０例正常健康妇女血清ＳＦ（铁蛋白）、β２－ＭＧ（β２－微球蛋白）、ＣＥＡ、ＬＤＨ、ＡＦＰ和β－ｈＣＧ进行定量检测。结果表明：①卵巢恶性肿瘤组血清ＳＦ、β２－ＭＧ、ＣＥＡ及ＬＤＨ含量均显著高于卵巢良性肿瘤组及正常对照组（Ｐ＜０．０１）；ＳＦ含量与肿瘤分期呈正相关，随卵巢恶性肿瘤临床期别增高而递增。ＡＦＰ、β－ｈＣＧ含量在卵巢良、恶性肿瘤组间及正常对照组间均无显著差异，提示血清ＳＦ、β２－ＭＧ、ＣＥＡ和ＬＤＨ检测，对卵巢恶性肿瘤的诊断及卵巢良、恶性肿瘤的鉴别诊断有一定临床意义。②ＳＦ、β２－ＭＧ、ＣＥＡ及ＬＤＨ诊断卵巢恶性肿瘤的准确性分别为７９．４４％、６９．１６％、６５．４０％及５６．０７％，四项联合准确性可提高到８３．１８％，提示：联合检测可提高临床诊断价值，优于单项检测结果。联合检测并结合病史及临床检查，可作为卵巢癌的初筛检查。
Serum SF (ferritin), β2-MG (β2-microglobulin), CEA, LDH, AFP and β-hCG in 107 ovarian cancer patients and 50 normal healthy women were detected by radioimmunoassay and biochemical methods. The results showed that: ① The levels of serum SF, β2-MG, CEA and LDH in ovarian cancer group were significantly higher than those in benign ovarian tumor group and normal control group (P <0.01); SF content was positively correlated with tumor stage, The clinical stage of the tumor increased and increased. AFP, β-hCG levels in ovarian benign and malignant tumor group and normal control group showed no significant difference, suggesting that serum SF, β2-MG, CEA and LDH detection of ovarian cancer diagnosis and ovarian benign and malignant tumors Differential diagnosis has some clinical significance. ② The accuracy of SF, β2-MG, CEA and LDH in the diagnosis of ovarian cancer were 79.44%, 69.16%, 65.40% and 56.07% respectively, and the accuracy of the four combinations could be improved to 83.18% , Tip: Joint testing can improve the clinical diagnostic value, better than the individual test results. Joint detection and combined with medical history and clinical examination, can be used as a screening test for ovarian cancer.